[Federal Register Volume 82, Number 96 (Friday, May 19, 2017)]
[Notices]
[Pages 23013-23014]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10154]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive Patent License: The Development of 
Monospecific and Bispecific Antibodies to GPC3 for the Treatment of 
Human Liver Cancers

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an Exclusive Patent License to AbPro, located in Woburn, Massachusetts, 
to practice the inventions embodied in the patent applications listed 
in the SUPPLEMENTARY INFORMATION section of this notice.

DATES: Only written comments and/or applications for a license which 
are received by the NCI Technology Transfer Center on or before June 5, 
2017 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
and comments relating to the contemplated Exclusive Patent License 
should be directed to: David A. Lambertson, Ph.D., Senior Licensing and 
Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center 
Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail), 
Rockville, MD 20850-9702, Telephone: (240)-276-6467; Email: 
[email protected].

SUPPLEMENTARY INFORMATION: The following represents the intellectual 
property to be licensed under the prospective agreement: U.S. 
Provisional Patent Application 61/654,232 entitled ``High-affinity 
Monoclonal Antibodies To Glypican-3 And Use Thereof'' [HHS Ref. E-136-
2012/0-US-01], PCT Patent Application PCT/US2013/043633 entitled 
``High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof'' 
[HHS Ref. E-136-2012/0-PCT-02], Chinese Patent Application 
201380039993.7 entitled ``High-affinity Monoclonal Antibodies To 
Glypican-3 And Use Thereof'' [HHS Ref. E-136-2012/0-CN-03], Japanese 
Patent Application 2015-515243 entitled ``High-affinity Monoclonal 
Antibodies To Glypican-3 And Use Thereof'' [HHS Ref. E-136-2012/0-JP-
04], South Korean Patent Application 10-2014-7037046 entitled ``High-
affinity Monoclonal Antibodies To Glypican-3 And Use Thereof'' [HHS 
Ref. E-136-2012/0-KR-05], Singapore Patent Application 11201407972R 
entitled ``High-affinity Monoclonal Antibodies To Glypican-3 And Use 
Thereof'' [HHS Ref. E-136-2012/0-SG-06], and United States Patent 
9,409,994 entitled ``High-affinity Monoclonal Antibodies To Glypican-3 
And Use Thereof'' [HHS Ref. E-136-2012/0-US-07], and all continuing 
U.S. and foreign patents/patent applications for the technology family, 
to AbPro. The patent rights in these inventions have been assigned to 
and/or exclusively licensed to the Government of the United States of 
America.
    With respect to persons who have an obligation to assign their 
right, title and interest to the Government of the United States of 
America, the patent rights in these inventions have been assigned to 
the Government of the United States of America.
    The prospective Exclusive Patent License territory may be worldwide 
for the following field of use:

    The use of the YP7, YP8 and YP9.1 anti-GPC3 monoclonal 
antibodies as monospecific or bispecific antibodies for the 
treatment of liver cancer. The licensed field of use excludes any 
non-specified immunoconjugates, including, but not limited to, 
chimeric antigen receptors (CARs) and variants thereof, 
Immunotoxins, and antibody-drug conjugates (ADCs).

    The present inventions to be licensed concern monoclonal antibodies 
that are specific for the cell surface domain of GPC3: YP6, YP7, YP8, 
YP9 and YP9.1. These antibodies can potentially be used for the 
treatment of GPC3-expressing cancers such as HCC. By binding to and 
blocking GPC3 function, these antibodies can inhibit the growth of HCC 
cells, thereby decreasing the ability of tumors to grow and 
metastasize. Alternatively, the antibodies can be used to induce 
antibody-dependent anti-tumor activity by selectively killing cells 
which overexpress GPC3 while leaving healthy, normal cells unscathed. 
Finally, a secondary antibody capable of recruiting T cells to the 
tumor can be attached to the antibodies, thereby allowing for the 
localization of T cells or NK cells only to those cells which express 
GPC3, similarly leading to the selective killing of the cancer cells.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective Exclusive Patent License will be royalty 
bearing and may be granted unless within fifteen (15) days from the 
date of this published notice, the National Cancer Institute receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR part 404.

[[Page 23014]]

    Complete applications for a license in the prospective field of use 
that are timely filed in response to this notice will be treated as 
objections to the grant of the contemplated Exclusive Patent License. 
Comments and objections submitted to this notice will not be made 
available for public inspection and, to the extent permitted by law, 
will not be released under the Freedom of Information Act, 5 U.S.C. 
552.

    Dated: May 11, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2017-10154 Filed 5-18-17; 8:45 am]
 BILLING CODE 4140-01-P